+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Market and Future Potential for Molecular Point of Care

  • ID: 5241526
  • Report
  • January 2021
  • Region: Global
  • 115 Pages
  • Kalorama Information

FEATURED COMPANIES

  • Abbott Laboratories
  • binx health, inc.
  • Cepheid
  • DiaSorin S.p.A
  • Meridian Bioscience, Inc.
  • QuantuMDx Group

This report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings. Major IVD companies such as Abbott and Roche and Quidel compete, but there are many other and new entrants since our last reporting.

Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than an existing point of care systems. Development of new systems and menu expansion on existing lines is constant. The analyst defines molecular point of care or mPOC as consisting of devices marketed to customers outside the reference lab that run PCR or other DNA and RNA testing on a device with a small footprint. mPOC systems tend to have a result time fast enough for an office visit or bedside consultation. These systems feature cartridges or reduced preparation steps and limited interpretation of test results.

This was a subset of the testing industry still proving its merit to customers early last year, but certainly, the COVID-19 pandemic has been an influence on the market, as we suggested in the last report. The ability to deliver rapid PCR results has put them in the right place with the right function at the right time.  This report features a complete update on mPOC and COVID-19. It also discusses other growth areas.

The data in The Market and Future Potential for Molecular Point of Care includes information on systems and competitor analysis, as well as data on the size and growth of the market:

  • Current Molecular POC Systems
  • Molecular Point of Care Market: 2020-2025
  • COVID mPOC Market
  • Molecular Point of Care Market Share by Vendor, 2020 ($M, %)
  • Small-Footprint Molecular Point of Care Market, 2020 (%)
  • Geographic Breakout of the Molecular Point of Care Market, 2020 (N. America, Europe, APAC, RoW)
  • Segment Breakout of Molecular Point of Care Market, 2020 (Respiratory vs. Other)
  • Breakout of Molecular Point of Care Market, 2020 (%; Respiratory, Other)
  • Respiratory Segment Breakout, 2020 (Flu, RSV, Strep, Other)
  • Breakout of mPOC Respiratory, 2020 (%; Flu, Strep, RSV, Other)
  • Near Patient Molecular IVD Market: 2020-2025
  • Near Patient Molecular Market Share by Vendor, 2020
  • Company Profiles

Many trends are covered in the report, including menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC and other trends.

Table 1-2: Near Patient Molecular Systems Market: 2020-2025

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • binx health, inc.
  • Cepheid
  • DiaSorin S.p.A
  • Meridian Bioscience, Inc.
  • QuantuMDx Group

CHAPTER ONE: EXECUTIVE SUMMARY

WHERE IS MOLECULAR POINT OF CARE IN 2021?
MOLECULAR POINT OF CARE MARKET ANALYSIS

  • Table 1-1: Molecular Point of Care Market: 2019-2024
  • Figure 1-1: mPOC Market by Disease Indication, 2019 (%; Respiratory, Other)

Market Observations
“Near-Patient” Molecular Systems Market

  • Table 1-2: Near Patient Molecular Systems Market: 2019-2024

CURRENT TRENDS
COVID-19 and mPOC
MOLECULAR POINT-OF-CARE DIAGNOSTICS DEFINED
USAGE OF MOLECULAR POINT OF CARE
LEADING MPOC PLATFORMS

  • Table 1-3: Market-Available Molecular POC Diagnostic Platforms

TRENDS
SCOPE AND METHODOLOGY

CHAPTER TWO: MOLECULAR POINT-OF-CARE MARKET DEVELOPMENT AND TRENDS

ADVANTAGES AND DISADVANTAGES OF MOLECULAR POINT OF CARE

  • Table 2-1: Disadvantages of Molecular Point of Care, by Setting

JUSTIFICATION: THE SENSITIVITY/SPECIFICITY ARGUMENT
NEW SYSTEMS AND MENU EXPANSION

  • Table 2-2: Recent Menu Expansions for Hospital and POC Molecular Platforms (Vendor, Platform, Menu Addition, Time to Results, CLIA-waiver, US/EU Availability)

INVESTMENT IN MPOC SYSTEMS
CHINA AS A POC MARKET
COMMON TESTS AND ANALYTES IN POC DIAGNOSTICS
COMPONENT TECHNOLOGIES OF MOLECULAR POINT-OF-CARE DIAGNOSTICS
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
MOLECULAR DIAGNOSTICS
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Line Probe Assays
Next-Generation Sequencing
APPLICATIONS AND POTENTIAL APPLICATIONS FOR MOLECULAR POINT-OF-CARE
COVID-19
Major Testing Applications for Molecular POC Diagnostics
Influenza
Hospital-Acquired Infections (HAIs)
Strep A
Respiratory Syncytial Virus (RSV)
EMERGING APPLICATIONS
Other Respiratory Infections
Group B Streptococcus
STDs
Tuberculosis
Malaria
Other Tropical and Neglected Diseases
Cancer
EUROPEAN DEVICE REGULATIONS NEARING

CHAPTER THREE: MARKET ANALYSIS

MOLECULAR POINT OF CARE MARKET ANALYSIS

  • Table 3-1: Molecular Point of Care Market: 2019-2024
  • Table 3-2: Molecular Point of Care Market Share by Vendor, 2019 ($M, %)
  • Figure 3-1: Small-Footprint Molecular Point of Care Market, 2019 (%)
  • Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2019 (N. America, Europe, APAC, RoW)
  • Table 3-4: Segment Breakout of Molecular Point of Care Market, 2019 (Respiratory vs. Other)
  • Figure 3-2: Breakout of Molecular Point of Care Market, 2019 (%; Respiratory, Other)

Respiratory Molecular Point of Care Segmentation

  • Table 3-5: Respiratory Segment Breakout, 2019 (Flu, RSV, Strep, Other)
  • Figure 3-3: Breakout of mPOC Respiratory, 2019 (%; Flu, Strep, RSV, Other)

“NEAR PATIENT MOLECULAR” MARKET

  • Table 3-6: Near Patient Molecular IVD Market: 2019-2024

Market Share Near Patient

  • Table 3-7: Near Patient Molecular Market Share by Vendor, 2019

CHAPTER FOUR: COMPANY PROFILES

ABBOTT LABORATORIES
AIDIAN OY
AKONNI BIOSYSTEMS
BINX HEALTH, INC.
BIOCARTIS NV
BIOMÉRIEUX SA
CEPHEID

  • Molecular Healthcare-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women’s Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology/Genetics Testing

CREDO BIOSCIENCE
CURETIS NV
DIASORIN S.P.A
GENMARK DIAGNOSTICS
GREINER BIO-ONE GMBH
MERIDIAN BIOSCIENCE, INC.
MESA BIOTECH, INC.
QIAGEN NV
QUANTUMDX GROUP
QUIDEL CORPORATION
ROCHE
SEKISUI DIAGNOSTICS LLC
T2 BIOSYSTEMS

Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMérieux SA
  • Cepheid
  • Credo Bioscience
  • Curetis NV
  • DiaSorin S.p.A
  • GenMark Diagnostics
  • Greiner Bio-One GmbH
  • Meridian Bioscience, Inc.
  • Mesa Biotech, Inc.
  • QIAGEN NV
  • QuantuMDx Group
  • Quidel Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems
Note: Product cover images may vary from those shown
Adroll
adroll